The new report entitled Extensive-Disease Small-Cell Lung Cancer : New Entrants Will Offer Only Incremental Improvements in Patient Outcomes also finds that a drug 's effect on median overall survival is the drug attribute that most influences surveyed oncologists prescribing decisions in extensive-disease small-cell lung cancer .